(Q39284974)

10 September 2017

Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth (English)

1 reference

10 September 2017

2

Cédric Rébé

0 references

François Ghiringhelli

8

François Ghiringhelli

0 references

Lionel Apetoh

7

Lionel Apetoh

0 references

Mélanie Bruchard

5

Mélanie Bruchard

0 references

Grégoire Mignot

9

Grégoire Mignot

0 references

author name string

Alice Hervieu

1

1 reference

10 September 2017

Frédérique Végran

3

1 reference

10 September 2017

Fanny Chalmin

4

1 reference

10 September 2017

Pierre Vabres

6

1 reference

10 September 2017

language of work or name

English

0 references

publication date

6 September 2012

1 reference

Journal of Investigative Dermatology

10 September 2017

1 reference

10 September 2017

133

1 reference

10 September 2017

2

1 reference

10 September 2017

499-508

1 reference

https://scigraph.springernature.com/pub.10.1038/jid.2012.273

10 September 2017

0 references

cites work

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Immunogenicity of anthracyclines: moving towards more personalized medicine

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Effect of NKG2D ligand expression on host immune responses

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Experimental mouse tumour models: what can be learnt about human cancer immunology?

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Unique Functional Status of Natural Killer Cells in Metastatic Stage IV Melanoma Patients and Its Modulation by Chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Induction of NKG2D ligands by gamma radiation and tumor necrosis factor-alpha may participate in the tissue damage during acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Combination Chemotherapy in Disseminated Melanoma and Other Solid Tumors in Adults

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Immunotherapy of malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Ipilimumab plus dacarbazine in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Treatments for metastatic melanoma: synthesis of evidence from randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Regulation of ligands for the activating receptor NKG2D.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Stress-regulated targeting of the NKG2D ligand Mult1 by a membrane-associated RING-CH family E3 ligase

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Calreticulin exposure dictates the immunogenicity of cancer cell death

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Soluble NKG2D ligands: prevalence, release, and functional impact.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

CTLA-4 blockade: therapeutic potential in cancer treatments

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Immunological aspects of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Interferon-gamma treatment of B16 melanoma cells: opposing effects for non-adaptive and adaptive immune defense and its reflection by metastatic spread

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.273

7 January 2021

Identifiers

DOI

10.1038/JID.2012.273

1 reference

Dimensions Publication ID

10 September 2017

1005047084

0 references

Fatcat ID

release_y44hgl5gtrbutayndcqltxmrwi

0 references

1 reference